Agilent Strengthens Pathology Capabilities Through Biocare Acquisition

Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group. The combination expands a pathology portfolio spanning clinical and research settings.

Biocare provides immunohistochemistry (IHC) and molecular pathology solutions, including automated instrumentation, high-quality reagents, and simultaneous multiplexing technologies that support cancer diagnostics and research. Its staining solutions are designed to produce high-quality images on every slide and help strengthen diagnostic accuracy. The company also positions the platform as digital-ready for the future of pathology.

Agilent Technologies, Inc. is a global provider of analytical and clinical laboratory technologies, offering instruments, software, services, and expertise that help customers advance scientific discovery. The company reported USD 6.95 billion in fiscal 2025 revenue and employs approximately 18,000 people worldwide.

“We are pleased to complete our acquisition of Biocare, which represents a natural and strategic expansion of Agilent’s pathology portfolio and strengthens our ability to serve customers across clinical and research settings,” said Padraig McDonnell, president and CEO, Agilent Technologies.

“At Agilent, we remain focused on investing in areas where we see clear opportunities to enhance our capabilities, accelerate customer-centric innovation and create long-term value for our shareholders. With Biocare’s talented team and complementary portfolio now part of Agilent, we are well positioned to build on our momentum and further support the evolving needs of our customers and partners,” McDonnell said.